Tarsus Pharmaceuticals, Inc. (TARS) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to TARSA's second quarter 2025 earnings conference call. As a reminder, this call is being recorded. At this time, I would like to turn the call over to David Nakasane, head of investor relations, to lead off the call. David, you may begin. Thank you. Before we begin, I encourage everyone to visit the investor section of the TARCIS website to view the earnings release and related materials we will be discussing today. Joining me on the call this afternoon are Bobby Azamian, our Chief Executive Officer and Chairman, Aziz Madawala, our Chief Commercial Officer, and Jeff Farrell, our Chief Financial Officer and Chief Strategy Officer. I'd like to draw your attention to slide three, which contains our forward-looking statements. During this call, we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional details. With that, I will turn the call over to Bobby. Thank you, Dave. Good afternoon, everyone, and thank you for joining us. We are approaching the two-year anniversary of the launch of Xtembe. the first and only FDA-approved treatment for demodex blepharitis. In that time, we've established a new category in eye care and executed one of the most successful launches ever in the prescription eye drop market. This success is more than a milestone. It's powerful validation of our scientific innovation, strategy, and leadership, and a clear signal that our vision of becoming the next leader in eye care isn't just aspirational, It's already taking shape with m...